China, L;
Freemantle, N;
Forrest, E;
Kallis, Y;
Ryder, SD;
Wright, G;
O'Brien, A;
(2021)
Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial.
The American Journal of Gastroenterology
, 116
pp. 2292-2295.
10.14309/ajg.0000000000001488.
Preview |
Text
Freemantle_Hyponatremia.SupplementaryMaterial.pdf - Accepted Version Download (332kB) | Preview |
Preview |
Text
Freemantle_HyponatremiaAJG.Revised.Clean.pdf - Accepted Version Download (186kB) | Preview |
Abstract
INTRODUCTION: Patients with decompensated cirrhosis and hyponatremia have a poor prognosis. We investigated Albumin to Prevent Infection in Chronic Liver Failure trial data to determine whether targeted albumin infusions improved outcome in patients with hyponatremia at baseline. METHODS: We examined the interaction between targeted albumin and standard care for the composite primary end point, stratifying by baseline sodium ≥ and <130 mmol/L. RESULTS: Randomization to albumin was associated with a significant increase in sodium; however, there was no interaction between sodium category and treatment for the trial primary end point. DISCUSSION: Targeted intravenous albumin infusions increased serum sodium level in hospitalized hyponatremic patients with cirrhosis, but this did not improve outcome.
Archive Staff Only
 |
View Item |
